[2] N.J. White, Determinants of relapse periodicity in Plasmodium vivax malaria, Malar. J. 10 (2011).
[3] S. Kumar, T.R. Bhardwaj, D.N. Prasad, R.K. Singh, Drug targets for resistant malaria: Historic to future perspectives, Biomed. Pharmacother. 104 (2018) 8–27.
[4] S. Abbat, V. Jain, P. V. Bharatam, Origins of the specificity of inhibitor P218 toward wild-type and mutant PfDHFR: A molecular dynamics analysis, J. Biomol. Struct. Dyn. 33 (2015) 1913–1928.
[5] B. Tarnchompoo, P. Chitnumsub, A. Jaruwat, P.J. Shaw, J. Vanichtanankul, S. Poen, R. Rattanajak, C. Wongsombat, A. Tonsomboon, S. Decharuangsilp, T. Anukunwithaya, U. Arwon, S. Kamchonwongpaisan, Y. Yuthavong, Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance, ACS Med. Chem. Lett. 9 (2018) 1235–1240.
[6] AutoDock Vina – molecular docking and virtual screening program. http://vina.scripps.edu/manual.html#fe atures (accessed July 27, 2020).
[7] Vanichtanankul J, Taweechai S, Yuvaniyama J, Vilaivan T, Chitnumsub P, Kamchonwongpaisan S, Yuthavong Y Trypanosomal dihydrofolate reductase reveals natural antifolate resistance ACS Chem. Biol. 6 (2011) 905-911.